3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
8
Thoracic
2
Genitourinary
2
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous-Cell Non-Small-Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
Carboplatin
542
Pemetrexed
392
pembrolizumab
372
Cisplatin
356
Paclitaxel
285
Docetaxel
240
Gemcitabine
168
Nivolumab
158
Erlotinib Hydrochloride
147
Bevacizumab
114
atezolizumab
104
osimertinib
99
durvalumab
92
Etoposide
90
Gefitinib
68
130-nm albumin-bound paclitaxel
65
Cetuximab
64
Ipilimumab
60
Drug Therapy
51
Topotecan
48
Injections
44
Afatinib
41
tislelizumab
40
Cyclophosphamide
39
Albumin-Bound Paclitaxel
37
Vinorelbine
36
Crizotinib
34
cemiplimab
31
icotinib
26
Radiotherapy
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
bemarituzumab
×
Thoracic
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled
NCT05267470
2025-03-25
FORTITUDE-201
Amgen
Phase 1
Terminated
74 enrolled
22 charts